Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 5, 2026 | −$0.69 | −198.6% | $267.95M | −40.7% | −$0.91 |
| Q1 FY26ended Mar 31, 2026 | May 6, 2026 | −$0.56 | — | $246.09M | +87.0% | −$0.85 |
| Q4 FY25ended Dec 31, 2025 | — | −$1.65 | — | $203.33M | −10.3% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.80 | — | $156.72M | +17.1% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.70 | — | $452.05M | +100.7% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.93 | — | $131.61M | +10.1% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$0.66 | — | $226.58M | −30.2% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.95 | — | $133.81M | −7.2% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Ionis Pharmaceuticals shares, not any token. As of Aug 5, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 | — | −$0.45 | — | $225.25M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.98 | — | $119.50M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.06 | — | $324.51M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$1.03 | — | $144.21M | — | — |